Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for AZL30002

Result Summary for AZL30002

Result Summary

Protocol ID:	AZL30002
Clinical Study ID:	AZL30002 TRIZAL
Official Title:	A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL)
Phase:	Phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus I
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	C. Katlama, N. Clumeck, S. Fenske, J. Mallolas, A. Lafeuillade, L. Beauvais. Use of Trizivir to Simplify Therapy in HAART Experienced Patients with Long Term Suppression of HIV-RNA : TRIZAL Study (AZL30002) 24 Weeks Results. Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA. (Abstract / Poster Number 316) Lafeuillade A, Clumeck N, Mallolas J, Jaeger H, Livrozet JM, Ferreira Mdo S, Johnson M, Cheret A, Antoun Z; European Trizal team. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials. 2003 Jan-Feb;4(1):37-43 Katlama C, Fenske S, Gazzard B, Lazzarin A, Beauvais L. Switch to Trizivir versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL: AZL30002). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA. Abstract Number Oral #671